TargetBeta
HSD17B13
hydroxysteroid 17-beta dehydrogenase 13 · also SCDR9, SDR16C3 · Short chain dehydrogenase/reductase superfamily
1 program in company-led studies act on HSD17B13, from 1 company: 0 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule; the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| gatuzosiran | GlaxoSmithKline | phase 2 | 31 running | – | the company's pipeline |
Conditions their studies are in
- Liver Diseases, Alcoholic, 1 program
- Non-alcoholic Fatty Liver Disease, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Nov 26, 2027gatuzosiran · GlaxoSmithKline · phase 2 · NCT06613698
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.